This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARRB1 / Beta-arrestin-1 · IHC design guide
Design Immunohistochemistry for ARRB1
Plan chromogenic ARRB1 IHC in paraffin sections around the cytoplasmic and nuclear pattern reported in most tissues (HPA tissue IHC). Purkinje cells and nasopharyngeal goblet cells show high staining (HPA tissue IHC); GPCR stimulation can alter ARRB1 localisation (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARRB1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Most tissues show cytoplasmic and nuclear cell staining (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | GPCR stimulation can redistribute ARRB1 (UniProt) | |
| Regulation | Expression regulation is not annotated (UniProt) | |
| Isoform / epitope | 2 isoforms, 1A and 1B; check epitope coverage (UniProt) |
Section 1
Recommended ARRB1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by two published ARRB1 IHC protocols (PMC7348167; PMC4194125).
| Sample | Paraffin-embedded human kidney tissue; fixative not specified (datasheet M02185) |
| Fixation | Image fixative and duration unreported (datasheet M02185); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit monoclonal (clone CCB-1) anti-ARRB1, 1:50 (datasheet M02185) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARRB1-positive staining in purkinje cells of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteFor nuclear ARRB1, start with Tris-EDTA pH 9.0 HIER at 95–98 °C for 20 min (page retrieval rule); a published protocol also uses pH 9.0 microwave retrieval (PMC4194125).
Section 2
What Is the Expected ARRB1 Staining Pattern?
ARRB1 is a soluble protein with cytoplasmic and nuclear localization; it has no transmembrane segment (UniProt P49407 topology and subcellular location). In paraffin-section IHC, expect staining in many tissues, including Purkinje cells and nasopharyngeal goblet cells with reported high staining (HPA tissue IHC). HPA describes the overall pattern as cytoplasmic and nuclear and rates its tissue IHC profile Approved, pending external verification (HPA tissue IHC).
| Cytoplasmic and nuclear staining in Purkinje cells or nasopharyngeal goblet cells. | This matches the reported compartments and high staining in those cell types (HPA tissue IHC). Assess identifiable cells rather than treating every structure in the section as equally informative (general IHC practice). |
| Predominantly nuclear staining, with little visible cytoplasmic staining. | Nuclear staining can be plausible: UniProt places monomeric ARRB1 predominantly in the nucleus, and HPA reports nuclear tissue staining (UniProt P49407 subcellular location; HPA tissue IHC). An exclusively extracellular or structural pattern does not match those locations and merits an artefact check. |
| Strong staining in a cell population HPA lists as not detected, such as adipocytes. | The result conflicts with the reported staining for that specified cell type (HPA tissue IHC: adipocytes not detected). Consider cross-reactivity or endogenous detection activity; compare cellular morphology and detection-only controls before assigning ARRB1 positivity (general IHC practice). |
| Diffuse chromogen over cells and surrounding tissue, without clear cellular boundaries. | A widespread haze prevents reliable cytoplasmic or nuclear scoring (general IHC practice). Uneven blocking, detection background, or excess reagent can produce such staining; the HPA cellular pattern alone cannot identify which step caused it (HPA tissue IHC; general IHC practice). |
| No staining in a section containing identifiable Purkinje cells or nasopharyngeal goblet cells. | These are reported high-staining cell types, so their absence of signal prompts a technical review (HPA tissue IHC). Check tissue preservation, the IHC-validated antibody and detection controls; HPA's Approved profile remains pending external verification (HPA tissue IHC; general IHC practice). |
💡Expected ARRB1 appearanceCall a result positive when identifiable cells show cytoplasmic and/or nuclear signal, especially strong staining in Purkinje cells or nasopharyngeal goblet cells; diffuse extracellular chromogen is suspect (HPA tissue IHC; general IHC practice).
| Cell type and tissue context | HPA reports high staining in Purkinje cells and nasopharyngeal goblet cells, medium staining in several other named cell types, and no detected staining in some others (HPA tissue IHC). Score the specific cells present rather than labeling an entire tissue positive or negative. |
| Subcellular distribution | Cytoplasm and nucleus are both supported; UniProt also lists membrane-associated sites, coated pits and cytoplasmic vesicles, with recruitment linked to receptor stimulation (HPA tissue IHC; UniProt P49407 subcellular location). These annotations do not require visible membrane staining in every paraffin section. |
| IHC antibody evidence | HPA lists HPA070249 and CAB003763 as IHC Approved; its overall tissue profile is Approved, pending external verification (HPA antibodies; HPA tissue IHC). Approved is the supplied status; the payload does not assign either antibody IHC Enhanced validation. |
| Isoforms and epitope coverage | UniProt lists two isoforms, 1A and 1B (UniProt P49407 isoforms). The supplied sources do not map an IHC antibody epitope to either isoform, so an observed pattern cannot establish isoform-specific expression or antibody coverage. |
| Topology and processing | ARRB1 has no transmembrane segment or signal peptide and is annotated as a single chain spanning residues 1–418 (UniProt P49407 topology and processing). Interpret extracellular-only staining cautiously; these annotations do not establish a tissue-specific secretion or shedding pattern. |
| IF/ICC Q&A: Where is ARRB1 expected? | HPA supports nucleoplasmic localization and lists cytosol as an additional location in ICC-IF (HPA subcellular ICC-IF). This supports compartment interpretation for IF/ICC; it does not supply an IF/ICC protocol or make the paraffin-section IHC pattern identical. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in a reported high-staining cell type. | A failed staining run or unsuitable detection conditions are possibilities; HPA reports high staining in Purkinje cells and nasopharyngeal goblet cells but does not diagnose a failed section (HPA tissue IHC; general IHC practice). | Verify that the expected cells are present, then review the antibody's IHC validation, reagent preparation, antigen retrieval and detection controls (HPA antibodies; general IHC practice). No ARRB1-specific retrieval condition is supplied. |
| Only extracellular matrix or luminal material appears strongly stained. | That distribution does not fit the supplied cellular localization or lack of a signal peptide (HPA tissue IHC; UniProt P49407 subcellular location and processing). Nonspecific chromogen deposition is a possible technical cause (general IHC practice). | Inspect cells at higher magnification and compare a detection-only control before scoring the deposit as ARRB1 (general IHC practice). |
| A HPA-listed not-detected cell type appears strongly positive. | Cross-reactivity or endogenous detection activity may explain a conflicting result, though a single section cannot distinguish them (HPA tissue IHC; general IHC practice). | Confirm cell identity and review appropriate primary-omission and detection controls; compare staining in a reported high-staining cell type in the same run (HPA tissue IHC; general IHC practice). |
| Chromogen obscures boundaries across the section. | Excess detection signal or inadequate background control may prevent compartment assessment (general IHC practice). HPA reports a cellular cytoplasmic and nuclear pattern, not uniform tissue-wide haze (HPA tissue IHC). | Review blocking, washes and detection exposure using the assay's controls, then score only where cells and compartments remain distinguishable (general IHC practice). |
| Nuclear signal is called an artefact solely because cytoplasmic signal is weak. | That rule conflicts with HPA's nuclear tissue pattern and UniProt's predominantly nuclear monomer annotation (HPA tissue IHC; UniProt P49407 subcellular location). | Reassess identifiable nuclei alongside cellular background and controls; report the observed compartments without inferring stimulation state or oligomeric form from IHC alone (general IHC practice; UniProt P49407 subcellular location). |
| Results differ between an IHC section and an IF/ICC image. | HPA reports cytoplasmic and nuclear tissue IHC, while its ICC-IF summary supports nucleoplasm with additional cytosol (HPA tissue IHC; HPA subcellular ICC-IF). The supplied evidence does not establish identical assay patterns. | Interpret each result against its own HPA application evidence and antibody validation status; investigate controls before treating the difference as a biological change (HPA antibodies; HPA subcellular ICC-IF; general IHC practice). |
Experiment evidence
IHC & IF images showing ARRB1 staining
M02185 · IHCImmunohistochemical analysis of paraffin-embedded human kidney, using ARRB1 Antibody.
PA2155 · IHCAnti-beta Arrestin 1 antibody, PA2155, IHC(P) IHC(P): Human Mammary Cancer Tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000137486-ARRB1/tissue/cerebral+cortex#imid_20257625
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000137486-ARRB1/tissue/colon#imid_20257535
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000137486-ARRB1/tissue/liver#imid_20257552
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000137486-ARRB1/tissue/kidney#imid_20257553
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA049318; green = ARRB1, blue = nucleus, red = microtubules.
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA049318; green = ARRB1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARRB1 IHC & IF
🧪Run cerebellum first and require staining in Purkinje cells (HPA: High in Purkinje cells), then use heart muscle cardiomyocytes as a negative tissue (HPA: Not detected in cardiomyocytes). Within the cerebellum slide, treat cells outside the Purkinje-cell population as internal negatives only if they remain unstained in the validated assay; HPA does not identify a negative cell population on that slide.
Positive control tissue: Cerebellum (Purkinje cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARRB1 in Hep-G2, Rh30, U2OS, NIH 3T3, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, an isotype control matched to the primary antibody’s host species and clonality, and ARRB1-knockout tissue or a validated peptide-block control. For cerebellum, block endogenous peroxidase and inspect an unstained section for pigment that could be mistaken for chromogen.
⚠️Feasibility: A target-specific fixation window and effect are unreported in the supplied evidence; the selected M02185 paraffin-section kidney caption does not state a fixative (catalog caption: fixative unreported). Retrieval dependency is also unreported, and the supplied evidence does not establish whether frozen sections or IF are easier than paraffin IHC; ICC-IF images show supported nucleoplasmic localization (HPA: nucleoplasm supported). In cerebellum, distinguish possible pigment from true Purkinje-cell chromogen signal using the unstained and no-primary controls.
HPA tissue IHC evidence for ARRB1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Purkinje cells | High | Protein (IHC) | HPA → |
| Nasopharynx | Goblet cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Breast | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Ciliated cells (cell body) | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Lymph node | Non-germinal center cells | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARRB1 IHC Tips
Troubleshoot ARRB1 staining in paraffin section chromogenic IHC using compartment patterns, tissue controls, and matched processing conditions.
How should I adjust retrieval when ARRB1 staining is weak in paraffin sections?
Start with Tris-EDTA at pH 9.0, heated to 95–98 °C for 20 min (page retrieval setting). If staining is weak, check that sections stayed covered by buffer, then compare a longer retrieval time on adjacent sections while keeping antibody and detection conditions identical (standard IHC practice). Judge improvement in both cytoplasm and nuclei, since both are reported ARRB1 compartments, and reject conditions that increase diffuse tissue background (HPA tissue IHC; standard IHC practice). Record heating, cooling, and staining conditions for each slide so any gain can be distinguished from run variation (standard IHC practice).
Can fixation explain weak ARRB1 staining in my paraffin sections?
ARRB1-specific sensitivity to fixation is unknown from the supplied evidence, so do not attribute a weak result to a particular fixative or fixation duration (selected M02185 caption: fixative not stated). The catalog image documents ARRB1 staining in paraffin-embedded human kidney, but its caption does not identify the fixative (selected M02185 caption). Compare sections with documented processing histories, keeping retrieval, antibody incubation, detection, and counterstain conditions matched before assigning a cause (standard IHC practice). Include a reference section in each run and note whether staining loss affects nuclei, cytoplasm, or the whole section; that pattern can guide controlled troubleshooting without establishing an ARRB1-specific fixation effect (HPA tissue IHC; standard IHC practice).
Which ARRB1 compartments should I assess in chromogenic IHC?
Assess nuclear and cytoplasmic staining separately: tissue IHC reports both across most tissues, while the subcellular record supports nucleoplasm with additional cytosol localisation (HPA tissue IHC; HPA subcellular). Membrane-associated or punctate cytoplasmic signal can also be plausible because ARRB1 relocates to the plasma membrane and occurs in clathrin-coated pits and cytoplasmic vesicles (UniProt P49407 localisation). Score those patterns only when cell boundaries and puncta are resolved above adjacent background on the same section (standard IHC practice). Record the fraction of cells in each compartment rather than treating a change in distribution as a simple increase or decrease in total staining (standard IHC practice).
What can this stain establish about ARRB1 isoforms or modified epitopes?
ARRB1 has 2 listed isoforms, 1A and 1B, but the supplied antibody caption gives no epitope or isoform coverage, so a positive section cannot identify either isoform (UniProt P49407 isoforms; selected M02185 caption). The protein has no transmembrane segment and includes reported phosphorylation sites at Tyr-47 and Ser-412; those facts alone do not establish whether this antibody recognizes a modified or unmodified epitope (UniProt P49407 topology and modified residues). Check the catalog antibody's documented immunogen or epitope before making an isoform or phosphorylation claim (standard IHC practice). Until that information is available, report staining as ARRB1 immunoreactivity and retain compartment-specific scores (standard IHC practice).
How can I corroborate the IHC pattern with multiplex IF?
Use IF as a separate comparison and pair ARRB1 with a validated marker for the cell population being assessed; Purkinje cells and nasopharyngeal goblet cells are examples with high tissue IHC signal (HPA tissue IHC; standard IF practice). Choose fluorophores after inspecting unstained tissue autofluorescence, and place the weaker signal in a channel with good separation from that background (standard IF practice). Because ARRB1 lacks a transmembrane segment and can occupy nucleoplasm and cytosol, optimise permeabilisation to expose those intracellular epitopes without erasing spatial detail (UniProt P49407 topology; HPA subcellular; standard IF practice). Compare nuclear and cytosolic IF distributions with the chromogenic pattern without assuming identical processing or detection sensitivity (standard IF and IHC practice).
What should I check when ARRB1 chromogen appears diffuse?
Compare a no-primary control and an appropriate tissue control to distinguish detection-system background from antibody-associated signal (standard IHC practice). For peroxidase-based chromogenic detection, verify the peroxidase block and assess whether endogenous enzyme activity persists; treat DAB deposition as a workflow readout, not proof of ARRB1 identity (standard IHC practice). Reduce nonspecific staining by optimising blocking, antibody concentration, wash stringency, and chromogen development one variable at a time (standard IHC practice). Retain conditions that preserve resolved nuclear or cytoplasmic staining while reducing uniform haze, because both compartments are supported for ARRB1 and diffuse colour alone is hard to assign to cells (HPA tissue IHC; standard IHC practice).
How should I quantify ARRB1 staining across tissue regions? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region before scoring, then record nuclear and cytoplasmic ARRB1 separately because both distributions occur in tissue IHC (HPA tissue IHC; standard IHC practice). For each compartment, use an H-score combining staining intensity with percentage of positive cells, or report percentage positive when intensity categories are unreliable (standard IHC practice). If counting discrete positive cells, express density per mm² of evaluable tissue and normalise comparisons to the same cell population or tissue area across sections (standard IHC practice). Exclude folds, necrotic regions, and section edges using preset criteria, and keep retrieval and chromogen development consistent across samples (standard IHC practice).
How do I distinguish credible ARRB1 staining from artefact?
A credible result should show cell-resolved nuclear, cytoplasmic, or context-dependent membrane and vesicular staining, since these locations are reported for ARRB1 (HPA tissue IHC; UniProt P49407 localisation). High staining in cerebellar Purkinje cells or nasopharyngeal goblet cells can support a run, while staining confined to adipocytes or cardiomyocytes warrants closer review because those cells were reported as not detected (HPA tissue IHC). Check whether apparent positives instead follow section edges, damaged or necrotic areas, or residual endogenous peroxidase activity (standard IHC practice). Interpret a changed nuclear-to-cytoplasmic pattern as a distribution observation until matched controls establish staining specificity and comparable processing (HPA subcellular; standard IHC practice).
Boster reagents
Best ARRB1 / Beta-arrestin-1 IHC Antibodies
Anti-ARRB1 antibodies have IHC images from paraffin-embedded human kidney (M02185 caption) and human mammary cancer tissue (PA2155 caption); both list human, mouse and rat reactivity (catalog). IF is listed for M02185 (catalog).
Real IHC data
Anti-ARRB1/Beta Arrestin 1 Rabbit Monoclonal Antibody
Cat # M02185
Real IHC data
Anti-beta Arrestin 1/ARRB1 Antibody ®
Cat # PA2155
M02185 will render with a paraffin-embedded human kidney IHC image (M02185 caption); its applications include IHC and ICC/IF, with human, mouse and rat reactivity (catalog). PA2155 will render with a human mammary cancer tissue IHC(P) image (PA2155 caption); it lists IHC and human, mouse and rat reactivity (catalog).
Which to pick: For paraffin-section IHC, choose M02185 when its human kidney image is relevant (M02185 caption), or PA2155 when its human mammary cancer tissue image is relevant (PA2155 caption); neither caption reports the fixative. For IF/ICC, choose rabbit monoclonal M02185 because it lists both applications (M02185 catalog), though no IF image is supplied (catalog). For human, mouse or rat samples, either SKU lists reactivity (catalog); PA2155 has no IF/ICC listing (PA2155 catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P49407 (ARRB1_HUMAN, Beta-arrestin-1).
- Human Protein Atlas. ARRB1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARRB1 subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. ARRB1 antibody validation summary (3 antibodies).
- ARRB1 Drives Gallbladder Cancer Progression by Facilitating TAK1/MAPK Signaling Activation. Journal of Cancer 2021 — PMC7974532.
- Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis. Frontiers in molecular biosciences 2022 — PMC9538973.
- ARRB1 ameliorates liver ischaemia/reperfusion injury via antagonizing TRAF6-mediated Lysine 6-linked polyubiquitination of ASK1 in hepatocytes. Journal of cellular and molecular medicine 2020 — PMC7348167.
- Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. The EMBO journal 2014 — PMC4194125.
- PubMed PMID:8486659 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:9501202 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARRB1 (Beta-arrestin-1). Expected localisation Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: M02185 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Purkinje cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human kidney tissue; fixative not specified (datasheet M02185); 2. Fixation: Image fixative and duration unreported (datasheet M02185); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit monoclonal (clone CCB-1) anti-ARRB1, 1:50 (datasheet M02185); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: GPCR stimulation can redistribute ARRB1 (UniProt); Isoform / epitope: 2 isoforms, 1A and 1B; check epitope coverage (UniProt); Regulation: Expression regulation is not annotated (UniProt). Evidence: UniProt P49407, HPA tissue IHC · Approved, HPA ICC-IF · nucleoplasm., Datasheet M02185, PMC7348167, PMC4194125. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARRB1/immunohistochemistry-ihc-guide.